Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials

Reproductive BioMedicine Online

Volumn 35, Issue 5, 2017, Pages 529-535

  Mendoza, Nicolás ^a   Pérez, Laura ^a   Simoncini, Tommaso ^b   Genazzani, Alessandro ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

D chiro inositol; embryo quality; inositol; myo inositol; oocyte quality; polycystic ovary syndrome

Indexed keywords

INOSITOL;

COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; EMBRYO DEVELOPMENT; EMBRYO QUALITY; FEMALE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MEDLINE; META ANALYSIS; OOCYTE QUALITY; OUTCOME ASSESSMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SUPPLEMENTATION; SYSTEMATIC REVIEW; TREATMENT DURATION; WEB OF SCIENCE; DRUG EFFECT; OOCYTE;

FEMALE; HUMANS; INOSITOL; OOCYTES; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 85025811056     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/j.rbmo.2017.07.005     Document Type: Review

References (27)

1. Alpha Scientist in Reproductive Medicine and ESHRE Special Interest Group of Embriology. The Instanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum. Reprod 26 (2011), 1270–1283.
2. Artini, P.G., Di Berardino, O.M., Papini, F., Genazzani, A.D., Simi, G., Ruggiero, M., Cela, V., Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol 29 (2013), 375–379.
3. Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., Yildiz, B.O., The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod 31 (2016), 2841–2855.
4. Brusco, G.F., Mariani, M., Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur. Rev. Med. Pharmacol. Sci 17 (2013), 3095–3102.
5. Carlomagno, G., Unfer, V., Roseff, S., The D-chiro-inositol paradox in the ovary. Fertil. Steril 95 (2011), 2515–2516.
6. Chiu, T.T., Rogers, M.S., Law, E.L., Briton-Jones, C.M., Cheung, L.P., Haines, C.J., Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum. Reprod 17 (2002), 1591–1596.
7. Ciotta, L., Stracquadanio, M., Pagano, I., Carbonaro, A., Palumbo, M., Gulino, F., Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur. Rev. Med. Pharmacol. Sci 15 (2011), 509–514.
8. Colazingari, S., Treglia, M., Najjar, R., Bevilacqua, A., The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch. Gynecol. Obstet 288 (2013), 1405–1411.
9. Croze, M.L., Soulage, C.O., Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95 (2013), 1811–1827.
10. Emekçi Özay, Ö., Özay, A.C., Çağlıyan, E., Okyay, R.E., Gülekli, B., Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecol. Endocrinol 3 (2017), 1–5 Epub ahead of print.
11. Facchinetti, F., Bizzarri, M., Benvenga, S., D'Anna, R., Lanzone, A., Soulage, C., Di Renzo, G.C., Hod, M., Cavalli, P., Chiu, T.T., Kamenov, Z.A., Bevilacqua, A., Carlomagno, G., Gerli, S., Oliva, M.M., Devroey, P., Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur. J. Obstet. Gynecol. Reprod. Biol 195 (2015), 72–76.
12. Genazzani, A.D., Inositol as putative integrative treatment for PCOS. Reprod. Biomed. Online 33 (2016), 770–780.
13. Isabella, R., Raffone, E., Does ovary need D-chiro-inositol?. J Ovarian Res, 5, 2012, 14.
14. Mann, J.S., Lowther, K.M., Mehlmann, L.M., Reorganization of the endoplasmic reticulum and development of Ca2+ release mechanisms during meiotic maturation of human oocytes. Biol. Reprod 83 (2010), 578–583.
15. Minozzi, M., Nordio, M., Pajalich, R., The combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur. Rev. Med. Pharmacol. Sci 17 (2013), 537–540.
16. Monastra, G., Unfer, V., Harrath, A.H., Bizzarri, M., Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol. Endocrinol 33 (2017), 1–9.
17. Naderpoor, N., Shorakae, S., de Courten, B., Misso, M.L., Moran, L.J., Teede, H.J., Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum. Reprod. Update 21 (2015), 560–574.
18. Pacchiarotti, A., Carlomagno, G., Antonini, G., Pacchiarotti, A., Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol. Endocrinol 32 (2016), 69–73.
19. Papaleo, E., Unfer, V., Baillargeon, J.P., Fusi, F., Occhi, F., De Santis, L., Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil. Steril 91 (2009), 1750–1754.
20. Piomboni, P., Focarelli, R., Capaldo, A., Stendardi, A., Cappelli, V., Cianci, A., La Marca, A., Luddi, A., De Leo, V., Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin. J. Assist. Reprod. Genet 31 (2014), 1269–1276.
21. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod 19 (2004), 41–47.
22. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril 81 (2004), 19–25.
23. Saltiel, A.R., The role of glycosyl-phosphoinositides in hormone action. J. Bioenerg. Biomembr 23 (1991), 29–41.
24. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
25. Sun, T.H., Heimark, D.B., Nguygen, T., Nadler, J.L., Larner, J., Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myoinositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem. Biophys. Res. Commun 293 (2002), 1092–1098.
26. Unfer, V., Carlomagno, G., Rizzo, P., Raffone, E., Roseff, S., Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur. Rev. Med. Pharmacol. Sci 15 (2011), 452–457.
27. Unfer, V., Nestler, J.E., Kamenov, Z.A., Prapas, N., Facchinetti, F., Effects of inositol(s) in women with pcos: a systematic review of randomized controlled trials. Int. J. Endocrinol, 2016, 2016, 1849162.